Parasite | Eso | Sto | Cancer | ESD
2013³â ½ÃÁî¿ÀÄ« ¾Ï¼¾ÅÍÀÇ ³í¹®ÀÔ´Ï´Ù (Kakushima. United European Gastroenterol J. 2013). óÀ½ º¸´Â ÀâÁö¿¡ ½Ç·Á¼ ¹Ìó ¾ËÁö ¸øÇß½À´Ï´Ù. ¾ÆÁÖ ¼ÖÁ÷ÇÑ ³»¿ëÀÔ´Ï´Ù. ¸Å¿ì ÁÁÀº ³í¹®ÀÔ´Ï´Ù. Á¦°¡ ÁÁ¾ÆÇÏ´Â styleÀÌÁö¿ä. Á¤Á÷ÇÔ..... PDF fileµµ °ø°³µÇ¾î ÀÖ½À´Ï´Ù.
ESDÀÇ beyond expanded indicationÀ¸·Î ÆÇ´ÜÇÏ¿´´ø 104¸íÀÇ È¯ÀÚ¸¦ ¿©·¯ ÀÌÀ¯(°í·É 76, ȯÀÚÀÇ ¿äû 38, µ¿¹ÝÁúȯ 14, ŸÀå±â ¾Ç¼ºÁúȯ 6, gastric tube cancer 3)·Î ESD¸¦ ÇÏ¿´½À´Ï´Ù. Æò±Õ ½Ã¼ú½Ã°£ÀÌ 78ºÐ(ÃÖ´ë 420ºÐ)À̾ú°í õ°øÀÌ 14¿¹¿¡¼ ¹ß»ýÇÒ Á¤µµ·Î Èûµé¾úÁö¸¸, en-bloc resection with complete (R0) resectionÀº 74¿¹(71%)·Î ºñ±³Àû ÁÁ¾Ò½À´Ï´Ù. ´Ù¸¸ curative resectionÀº 17¿¹(16%)¹Û¿¡ µÇÁö ¾Ê¾Ò½À´Ï´Ù. ¿¹»óµÇ¾ú´ø °á°úÀÔ´Ï´Ù. Survivalµµ ¾ÆÁÖ ¼ÖÁ÷ÇÏ°Ô º¸¿©ÁÖ¾ú½À´Ï´Ù. ¿ª½Ã ESD¸¦ °³¹ßÇϽŠOno ¼±»ý´Ô ÆÀ¿¡¼ ³ª¿Â ³í¹®ÀÔ´Ï´Ù. ÈǸ¢ÇÕ´Ï´Ù.
2015³â ¼øõÇâ ºÎõº´¿øÀÇ ³í¹®ÀÔ´Ï´Ù (Kang MS. J Dig Dis. 2015). ÃÖÁ¾ º´¸®°á°ú·Î ¸ðÀº BEI (beyond expanded indication) º´¼ÒÀÇ en bloc resection rate´Â 86.3%·Î ºñ±³Àû ³ô¾ÒÀ¸³ª complete resection rate´Â 41.2%·Î ³·¾Ò½À´Ï´Ù. 5³â »ýÁ¸À²Àº 97.4%¿´À¸¸ç, 5³â disease free »ýÁ¸À²Àº 84.6%¿´½À´Ï´Ù. ÀúÀÚµéÀº ´ÙÀ½°ú °°ÀÌ °á·ÐÁþ°í ÀÖ¾ú½À´Ï´Ù. "Long-term outcomes of patients with BEI-EGC that did not receive additional surgery were better than those with an natural course of EGC. Thus, ESD may be considered for specific BEI-EGC patients at high risk for surgery."
¼¼ °¡Áö ±Ã±ÝÁõÀÌ ÀÖ½À´Ï´Ù. (1) ¾Æ·¡ Figure 1Àº ³Ê¹« ÁÁÀº ¼ºÀûÀÎÁö¶ó Àú·Î¼´Â Á¶±Ý ¹Ï¾îÁöÁö ¾Ê¾Ò½À´Ï´Ù. Àú´Â absolute indicationÀ̶ó°í »ý°¢ÇÑ È¯ÀÚ Áß¿¡¼µµ °¡²û beyond expanded indicationÀÌ ³ª¿Í ¼ö¼úÀ» ÇÏ´Â °æ¿ì¸¦ °æÇèÇÏ°í ÀÖ½À´Ï´Ù. ±×·± ȯÀÚ°¡ ÇÑ¸íµµ ¾ø´Ù´Ï ³î¶ø±â ±×Áö ¾ø½À´Ï´Ù. (2) ÃÖÁ¾º´¸®°á°ú·Î groupingÇÑ ¿¬±¸ÀÔ´Ï´Ù. Table 2¿¡¼ ¹ØÁÙÄ£ 9¸íÀº lymphovascular invasionÀÌ ÀÖ¾úÀ¸´Ï EI-EGC°¡ ¾Æ´Ï¶ó BEI-EGC¶ó°í º¸´Â °ÍÀÌ ÁÁÁö ¾ÊÀ»±î¿ä? (3) Beyond expanded indicationÀÇ Ä¡·á¿øÄ¢Àº ¼ö¼úÀÔ´Ï´Ù. ÀÌ ¿¬±¸¿¡¼ ¼ö¼úÇÑ È¯ÀÚ°¡ ¸î ¸í, ¼ö¼úÇÏÁö ¾ÊÀº ȯÀÚ°¡ ¸î ¸í, ¼ö¼úÇÏÁö ¾ÊÀº ÀÌÀ¯´Â ¹«¾ùÀÎÁö ±Ã±ÝÇÕ´Ï´Ù.
2015³â ´ë±¸°æºÏÁö¿ª ´Ù±â°ü °øµ¿¿¬±¸ÀÔ´Ï´Ù (Cho JY. Surg Endosc. 2015). SM invasion Áß 32.2% (38/118)¿¡¼ SM2 ÀÌ»óÀ̾ú½À´Ï´Ù. SM2 ÀÌ»ó(38)À̰ųª, SM1ÀÌÁö¸¸ expanded criteria°¡ ¾Æ´Ñ ȯÀÚ (Non-EC, 38) ¹× expanded criteria¿¡¼ noncurative resectionµÈ ȯÀÚ (NCR 13)Àº ¼ö¼ú ´ë»óÀÔ´Ï´Ù. ¼ö¼ú´ë»ó 89¸í Áß 38¸í(42.7%)ÀÌ ¼ö¼úÀ» ¹ÞÀ¸¼Ì½À´Ï´Ù. Àý¹ÝÀÌ»óÀÌ ¼ö¼úÀ» ¹ÞÁö ¾ÊÀº »óȲÀ̹ǷΠ´Ù¼Ò ¿ì·Á½º·´±â´Â ÇÕ´Ï´Ù. ³í¹®À» º¸½Ã¸é À§¾ÏÀ¸·Î Á×Àº ȯÀÚ°¡ 3¸íÀ̽ŵ¥ ±× Áß 2¸í(83¼¼ ³²ÀÚ, 83¼¼ ¿©ÀÚ)Àº ¼ö¼úÀ» ¹ÞÁö ¾ÊÀº ºÐÀÌ°í, 1¸í(73¼¼ ³²ÀÚ)´Â ¼ö¼úÀ» ÇßÀ½¿¡µµ ºÒ±¸ÇÏ°í À§¾ÏÀ¸·Î µ¹¾Æ°¡¼Ì´Ù°í ÇÕ´Ï´Ù. Absolute indicationÀ» ÃÊ°úÇϴ ȯÀÚ¿¡¼ ESD ÈÄ ¼ö¼ú±îÁö Çߴµ¥ Àç¹ßÇÏ¿© »ç¸ÁÇϽô ȯÀÚ´Â µå¹°Áö¸¸ °£È¤ ¹ß°ßµÇ°í ÀÖ½À´Ï´Ù. ¿ª½Ã ¾ÏÀº ¾ÏÀÔ´Ï´Ù.
(2015) ESD ÈÄ Ãµ°øÀ¸·Î °í»ýÀ» ¸¹ÀÌ ÇÏ¿´°í ¼ö¼úÀ» ±ÇÀ¯¹Þ¾Æ second opinion À§ÇØ ³»¿øÇϽŠȯÀÚÀÔ´Ï´Ù. ½ÉÇß±º¿ä.
© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.